WO2007118423A1 - Protéines de fusion d'érythropoïétine de recombinaison d'origine humaine, procédés d'élaboration et utilisations - Google Patents

Protéines de fusion d'érythropoïétine de recombinaison d'origine humaine, procédés d'élaboration et utilisations Download PDF

Info

Publication number
WO2007118423A1
WO2007118423A1 PCT/CN2007/001209 CN2007001209W WO2007118423A1 WO 2007118423 A1 WO2007118423 A1 WO 2007118423A1 CN 2007001209 W CN2007001209 W CN 2007001209W WO 2007118423 A1 WO2007118423 A1 WO 2007118423A1
Authority
WO
WIPO (PCT)
Prior art keywords
epo
fusion protein
anemia
cells
amino acids
Prior art date
Application number
PCT/CN2007/001209
Other languages
English (en)
Chinese (zh)
Inventor
Weiyue Han
Kai He
Liming Yang
Yong Yang
Renhuai Zhang
Delin Liu
Yalei Wen
Jikan Lin
Original Assignee
Beijing Genetech Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Genetech Pharmaceutical Co., Ltd. filed Critical Beijing Genetech Pharmaceutical Co., Ltd.
Publication of WO2007118423A1 publication Critical patent/WO2007118423A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Protéines de fusion d'érythropoïétine de recombinaison d'origine humaine (rhEPO), leurs polynucléotides de codage et leur procédés d'élaboration. Les structures primaires de terminaison N à terminaison C de ces protéines sont représentées par EPO-L-Fc, sachant qu'EPO correspond à érythropoïétine, que L est un peptide de liaison ayant entre 1 et 15 résidus d'acide aminés série qui sont glycine ou sérine, et que Fc est lgGFc d'origine humaine. Ces protéines ont une demi-vie de sérum plus longue que l'érythropoïétine naturelle.
PCT/CN2007/001209 2006-04-14 2007-04-13 Protéines de fusion d'érythropoïétine de recombinaison d'origine humaine, procédés d'élaboration et utilisations WO2007118423A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2006100722291A CN100436482C (zh) 2006-04-14 2006-04-14 长效人促红细胞生成素融合蛋白及其制备和纯化方法
CN200610072229.1 2006-04-14

Publications (1)

Publication Number Publication Date
WO2007118423A1 true WO2007118423A1 (fr) 2007-10-25

Family

ID=37483498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/001209 WO2007118423A1 (fr) 2006-04-14 2007-04-13 Protéines de fusion d'érythropoïétine de recombinaison d'origine humaine, procédés d'élaboration et utilisations

Country Status (3)

Country Link
CN (1) CN100436482C (fr)
HK (1) HK1098165A1 (fr)
WO (1) WO2007118423A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870735B (zh) * 2010-06-02 2013-06-12 北京精益泰翔技术发展有限公司 一种新型高糖基化促红细胞生成素免疫融合蛋白
CN105884906B (zh) * 2016-05-27 2021-11-19 广州太力生物医药科技有限公司 一种长效人促红细胞生成素融合蛋白的纯化方法
CN107937425A (zh) * 2017-12-27 2018-04-20 北京四环生物制药有限公司 长效重组人促红素的生产方法
CN114921443B (zh) * 2022-05-05 2023-07-07 重庆医科大学 肺炎链球菌肽链内切酶o在制备抗肿瘤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036489A2 (fr) * 1999-11-12 2001-05-25 Merck Patent Gmbh Formes d'erythropoietine dotees de proprietes ameliorees
CN1403483A (zh) * 2001-08-17 2003-03-19 旭华（上海）生物研发中心有限公司 生物活性提高的人促红细胞生成素的Fc融合蛋白
CN1521192A (zh) * 2003-01-30 2004-08-18 旭华（上海）生物研发中心有限公司 具有高度生物活性的人促红细胞生成素的Fc融合蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US7146012B1 (en) * 1997-11-22 2006-12-05 Koninklijke Philips Electronics N.V. Audio processing arrangement with multiple sources
CN1143895C (zh) * 2001-02-27 2004-03-31 李欣越 用基因工程方法生产增强其生物活性的红细胞生长因子二联体/三联体融合蛋白
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036489A2 (fr) * 1999-11-12 2001-05-25 Merck Patent Gmbh Formes d'erythropoietine dotees de proprietes ameliorees
CN1403483A (zh) * 2001-08-17 2003-03-19 旭华（上海）生物研发中心有限公司 生物活性提高的人促红细胞生成素的Fc融合蛋白
US20040175824A1 (en) * 2001-08-17 2004-09-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with high biological activities
US20050124045A1 (en) * 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
CN1521192A (zh) * 2003-01-30 2004-08-18 旭华（上海）生物研发中心有限公司 具有高度生物活性的人促红细胞生成素的Fc融合蛋白

Also Published As

Publication number Publication date
CN1872881A (zh) 2006-12-06
CN100436482C (zh) 2008-11-26
HK1098165A1 (en) 2007-07-13

Similar Documents

Publication Publication Date Title
JP4809977B2 (ja) 貧血の予防および治療用の方法および組成物
ES2314999T3 (es) Factor celular madre.
CA2406807C (fr) Methodes et compositions destinees a la prevention et au traitement de l'anemie
KR102202255B1 (ko) 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
WO2005084711A1 (fr) Erythropoietine recombinante pegylee a activite in vivo
JP2002534962A (ja) Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送
EA035956B1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
JP4153036B2 (ja) 截形グリア細胞系由来神経栄養因子
JP2002531089A (ja) 赤血球産生性化合物
CZ288890B6 (cs) MGDF polypeptid pro stimulaci růstu a diferenciaci megakaryocytů
AU2005283025A1 (en) Muteins of fibroblast growth factor 21
EP3121198B1 (fr) Dimère g-csf humain de recombinaison et son utilisation pour le traitement de maladies neurologiques
AU755078B2 (en) IFNAR2/IFN complex
AU732857B2 (en) Production and use of recombinant protein multimers with altered biological activity
WO2007118423A1 (fr) Protéines de fusion d'érythropoïétine de recombinaison d'origine humaine, procédés d'élaboration et utilisations
US20180273600A1 (en) Insulin secreting polypeptides
US20040241800A1 (en) Vascular endothelial growth factor dimers
JP2001515719A (ja) Ｍｐｌリガンド類似体
DK2618830T3 (en) Formulations to a kvæggranulocytkolonistimulerende factor and variants thereof
KR20210133947A (ko) 디프테리아 독소-인간 인터루킨-3 접합체를 다른 제제와 조합하여 사용해서 골수증식성 신생물을 치료하는 조합 치료 방법
WO2006061853A2 (fr) Nouveaux composes erythropoietiques et leur procede de production
WO2011147138A1 (fr) Protéine de fusion de l'interleukine de ciblage et son procédé de préparation et son utilisation
WO2022056493A1 (fr) Procédés pilotés par des biomarqueurs pour le traitement d'un trouble dépressif majeur
KR20220077590A (ko) Candida Utilis 유래 요산산화효소-알부민 복합체 및 이의 제조 방법
JPH05178899A (ja) 修飾ポリペプチドおよびそれを有効成分とする血小板減少症治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07720782

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07720782

Country of ref document: EP

Kind code of ref document: A1